Abstracts Archive - Page 1001 of 2607 - ACR Meeting Abstracts

Abstract Number: 913 • 2019 ACR/ARP Annual Meeting
Depression as a Moderator of Analgesic Effectiveness in Knee Osteoarthritis
Alan Rathbun¹, Michelle Shardell ², Joseph Gallo ³, Alice Ryan ¹, Elizabeth Stuart ³, Megan Schuler ⁴, Michelle Yau ⁵ and Marc C. Hochberg ¹, ¹University of Maryland School of Medicine, Baltimore, MD, ²National Institute on Aging, Baltimore, MD, ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁴RAND Corporation, Boston, MA, ⁵Hebrew SeniorLife Institute for Aging Research, Boston, MA
Background/Purpose: Depression often accompanies knee osteoarthritis (OA), exacerbating the severity and persistence of pain, and may negatively affect clinical outcomes associated with analgesic treatment. This…
Abstract Number: 914 • 2019 ACR/ARP Annual Meeting
The Effects of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Chronic Knee Pain in Older U.S. Adults
Lindsey MacFarlane¹, Nancy Cook ¹, Eunjung Kim ², I-Min Lee ¹, Maura D. Iversen ³, Julie Buring ¹, Jeffrey Katz ¹, JoAnn Manson ¹ and Karen Costenbader ⁴, ¹Brigham and Women's Hospital/Harvard Medical School, Boston, ²Brigham and Women's Hospital, Boston, ³Northeastern University, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: Chronic knee pain from osteoarthritis (OA) is frequent in the older adult population. Prior trials have had conflicting results concerning vitamin D’s therapeutic effects, and…
Abstract Number: 915 • 2019 ACR/ARP Annual Meeting
Development and Initial Validation of the Systemic JADAS, a New Composite Disease Activity Score for Systemic Juvenile Idiopathic Arthritis
Jessica Tibaldi¹, Yasser El Miedany ², Pryiankar Pal ³, Soamarat Vilaiyuk ⁴, Raju Khubchandani ⁵, Manuela Pardeo ⁶, Tapas Kumar Sabui ⁷, Sujata Sawhney ⁸, Ricardo Russo ⁹, Flavio Sztajnbok ¹⁰, Rolando Cimaz ¹¹, Francesca Minoia ¹², Motasem O. Alsuweiti ¹³, Ekaterina Alexeeva ¹⁴, Mikhail Kostik ¹⁵, Maria Cristina Maggio ¹⁶, Sulayman Al Mayouf ¹⁷, Claudia Saad ¹⁸, Giovanni Conti ¹⁹, Romina Gallizzi ²⁰, Adele Civino ²¹, Masaki Shimizu ²², Enrico Felici ²³, Angela Pistorio ²⁴, Nicolino Ruperto ²⁵, Alessandro Consolaro ²⁶ and Angelo Ravelli ²⁷, ¹IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genoa, Italy, ²Ain Shams University, Cairo, Egypt, ³Institute of Child Health, Kolkata, India, ⁴Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, ⁵Jaslok Hospital and Research Center, Mumbai, India, ⁶Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁷R G Kar Medical College, Kolkata, Kolkata, India, ⁸Department of pediatric rheumatology, Sir Ganga Ram Hospital, New Delhi, India, New Delhi, India, ⁹Hospital de Pediatría Garrahan, Buenos Aires, Argentina, ¹⁰Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹¹University Hospital Meyer, Florence, Italy, ¹²Clinica De Marchi Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ¹³Queen Rania Children's Hospital, Amman, Jordan, ¹⁴National Medical Research Center of Children`s Health, Moscow, Russia, ¹⁵Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, ¹⁶Università di Palermo, Dipartimento G. D'Alessandro, Palermo, Italy, ¹⁷King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, ¹⁸Hospital das Clínicas - Botucatu Medicine University, UNESP, Botucatu, Brazil, ¹⁹AOU G Martino, Messina, Italy, ²⁰Azienda Ospedaliera Universitaria Gaetano Martino, Messina, Messina, Italy, ²¹Pediatric Rheumatology “Vito Fazzi” Hospital, Lecce, Lecce, Italy, ²²Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa, Japan, ²³SS Antonio e Biagio e Cesare Arrigo" Hospital, Alessandria, Italy, ²⁴IRCCS Istituto Giannina Gaslini, Genova, Italy, ²⁵Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²⁶Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy and IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy, Genova, Italy, ²⁷IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy
Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) has gained increasing popularity for the measurement of the level of disease activity in patients with juvenile…
Abstract Number: 916 • 2019 ACR/ARP Annual Meeting
Development and Initial Validation of the MS Score for Diagnosis of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis
Francesca Minoia¹, Francesca Bovis ², Sergio Davì ³, AnnaCarin Horne ⁴, Michel Fischbach ⁵, Michael Frosch ⁶, Adam Huber ⁷, Marija Jelusic ⁸, Sujata Sawhney ⁹, Deborah McCurdy ¹⁰, Clovis Artur Silva ¹¹, Donato Rigante ¹², Erbil Unsal ¹³, Nicolino Ruperto ¹⁴, Alberto Martini ¹⁵, Randy Cron ¹⁶ and Angelo Ravelli ¹⁵, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Lombardia, Italy, ²Università degli Studi di Genova, Genoa, Italy, ³IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁴Karolinska University Hospital, Stockholm, Sweden, ⁵Hopital Universitaire Hautepierre, Strasbourg, France, ⁶School of Medicine Witten/Herdecke University, Datteln, Germany, ⁷IWK Health Centre, Halifax, NS, Canada, ⁸University of Zagreb, Zagreb, Croatia, ⁹Sir Ganga Ram Hospital, New Delhi, India, ¹⁰University of California, MDCC 12-430, 10833 Le Conte Ave, Los Angeles, 90095, CA, USA, Los Angeles, ¹¹Childrens’ Institute, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, ¹²Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ¹³Dokuz Eylul University, School of Medicie, Izmir, Turkey, ¹⁴Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁵IRCCS Istituto Giannina Gaslini, Università degli Studi di Genova, Genova, Italy, ¹⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Macrophage activation syndrome (MAS) is the most severe complication of systemic juvenile idiopathic arthritis (sJIA) and its adult equivalent, adult-onset Still’s disease (AOSD). Because…
Abstract Number: 917 • 2019 ACR/ARP Annual Meeting
Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors
Grant Schulert¹, Shima Yasin ², Brenna Carey ³, Claudia Chalk ³, Thuy Do ¹, Andrew Schapiro ³, Ammar Husami ³, Allen Watts ³, Hermine Brunner ⁴, Jennifer Huggins ³, Elizabeth Mellins ⁵, Esi Morgan ³, Tracy Ting ³, Bruce Trapnell ⁶, Katheryn Wikenheiser-Brokamp ³, Christopher towe ³ and Alexei A. Grom ¹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Stanford University, Palo Alto, ⁶Cincinnati Children's Hospital, Cincinnati
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is associated with a recently recognized albeit poorly defined and characterized lung disease (LD). Our objective is to describe…
Abstract Number: 918 • 2019 ACR/ARP Annual Meeting
Multiplex Serum Analysis Identifies Potential Biomarkers of Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome, and Associated Pulmonary Alveolar Proteinosis: Evidence for Independently-regulated Hyperinflammatory and Eosinophilic Inflammation
Guangbo Chen ¹, Grant Schulert ², Adriana De Jesus ³, Vivian Saper ⁴, Corinne Schneider ⁵, Bruce Trapnell ⁶, Alexei A. Grom ², Raphaela Goldbach-Mansky ⁷, Elizabeth Mellins ⁴, Purvesh Khatri ⁸ and Scott Canna⁹, ¹Stanford University, Palo Alto, CA, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³NIH/NIAID/TADS, Bethesda, MD, ⁴Stanford University, Palo Alto, ⁵University of Pittsburgh, Pittsburgh, ⁶Cincinnati Children's Hospital, Cincinnati, ⁷Translational Autoinflammatory Diseases Section/NIAID/NIH, Bethesda, MD, ⁸Institute for Immunity, Transplantation and Infection, Stanford University, Palo Alto, ⁹UPMC Children's Hospital of Pittsburgh, Pittsburgh
Background/Purpose: Recent experiences suggest a disturbing epidemic of digital clubbing and insidious, Pulmonary Alveolar Proteinosis (PAP)-like lung disease occurring in patients with Systemic Juvenile Idiopathic…
Abstract Number: 919 • 2019 ACR/ARP Annual Meeting
Free Interlukin-18: A New Promising Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
Shima Yasin¹, Emiliana Rodriguez ², Thuy Do ³, Elizabeth Baker ¹, Sanjeev Dhakal ³, Scott Canna ⁴, Cem Gabay ⁵, Alexei A. Grom ³ and Grant Schulert ³, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, ²Rheumatology, Geneva University Hospitals and University of Geneva, Switzerland, Geneva, Swaziland, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴UPMC Children's Hospital of Pittsburgh, Pittsburgh, ⁵Rheumatology, Geneva University Hospitals and University of Geneva, Switzerland, Geneva, Switzerland
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a childhood arthritis with features of autoinflammation, and is associated with high risk of macrophage activation syndrome (MAS).…
Abstract Number: 920 • 2019 ACR/ARP Annual Meeting
Adenosine Deaminase 2 as a Circulating Biomarker of Macrophage Activation Syndrome
Pui Lee¹, Grant Schulert ², Scott Canna ³, Yuelong Huang ⁴, Jacob Sundel ⁴, Mary Beth Son ¹, Lauren Henderson ¹, Peter Nigrovic ⁵, Jane Newburger ⁶, Fatma Dedeoglu ⁶, Mindy Lo ⁶, Esra Meidan ⁶, Ying Li ⁴, Olha Halyabar ⁶, Margaret Chang ⁷, Kacie Hoyt ⁶, Thuy Do ², Robert Sundel ⁸ and Rachel Blaustein ⁴, ¹Boston Children's Hospital, Boston, MA, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³UPMC Children's Hospital of Pittsburgh, Pittsburgh, ⁴Brigham and Women's Hospital, Boston, ⁵Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA ; Department of Medicine, Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA., Boston, ⁶Boston Children's Hospital, Boston, ⁷Division of Immunology, Boston Children's Hospital, Boston, ⁸Boston Children’s Hospital, Harvard Medical School, Boston
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA) characterized by a vicious cycle of immune cell activation and…
Abstract Number: 921 • 2019 ACR/ARP Annual Meeting
Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms
Jon Giles¹, Cecilia Chung ², Mary Chester Wasko ³, Amy Kao ³, Annette Oeser ², C. Michael Stein ² and Joan Bathon ⁴, ¹Columbia University, Vagelos College of Physicians & Surgeons, New York, NY, ²Vanderbilt University, Nashville, TN, ³Allegheny Health Network-West Penn Hospital, Pittsburgh, PA, ⁴Division of Rheumatology, Columbia University, New York, NY
Background/Purpose: In the general population, statins reduces atherosclerotic cardiovascular disease (ASCVD) events in those with a computed tomography (CT)-assessed coronary artery calcium (CAC) score ≥100…
Abstract Number: 922 • 2019 ACR/ARP Annual Meeting
Improved Incidence of Cardiovascular Disease in Patients with Incident Rheumatoid Arthritis in 2000s: A Population-Based Cohort Study
Elena Myasoedova¹, John Davis ¹, Veronique Roger ¹, Sara Achenbach ¹ and Cynthia Crowson ², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester
Background/Purpose: Increased burden of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) as compared to the general population is well recognized. Several studies suggested…
Abstract Number: 923 • 2019 ACR/ARP Annual Meeting
First Cardiovascular Event in Rheumatoid Arthritis: Do Patients with Venous Thromboembolism Have a Different Risk Profile Than Patients with Atherosclerotic Cardiovascular Disease?
Gulsen Ozen¹, Sofia Pedro ², Rebecca Schumacher ², Teresa Simon ³ and Kaleb Michaud ¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³Bristol-Myers Squibb*, Princeton, NJ
Background/Purpose: Chronic inflammation is linked to increased risk of cardiovascular disease (CVD) in RA that may manifest as venous thromboembolism (VTE) or atherosclerotic CVD (ASCVD).…
Abstract Number: 924 • 2019 ACR/ARP Annual Meeting
Highly-sensitive Cardiac Troponin-I and Beta-2-Glycoprotein-I IgA Antibodies Inform the Utility of Screening and Follow-up Non-invasive Coronary Atherosclerosis Evaluation and Optimize Cardiovascular Risk Assessment in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth ¹, Elizabeth Hernandez ² and Matthew Budoff ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA Medical center and Los Angeles Biomedical Research Institute, Torrance
Background/Purpose: We recently reported that highly-sensitive cardiac troponin-I (hs-cTnI) associates with occult coronary atherosclerosis burden and cardiovascular event (CVE) risk in rheumatoid arthritis (RA). We…
Abstract Number: 925 • 2019 ACR/ARP Annual Meeting
Incidence of Dementia and Association with Cardiovascular Disease and Risk Factors in Rheumatoid Arthritis – Analysis of a National Claims Database
Sebastian E. Sattui¹, Mangala Rajan ², Sarah Lieber ¹, Geyanne Lui ³, Jeffrey Curtis ⁴, Lisa Mandl ⁵ and Iris Navarro-Millan ², ¹Hospital for Special Surgery, New York, ²Weill Cornell Medicine, New York, ³Weill-Cornell Medicine, New York, NY, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY
Background/Purpose: Inflammation has been thought to be a risk factor for cognitive impairment and dementia. RA, an autoimmune inflammatory disorder is associated with a high…
Abstract Number: 926 • 2019 ACR/ARP Annual Meeting
Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification
Tate Johnson¹, Joshua Baker ², Punyasha Roul ¹, Harlan Sayles ¹, Grant Cannon ³, Brian Sauer ³, Ted Mikuls ⁴ and Bryant England ⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁴VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁵VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha
Background/Purpose: Rheumatoid arthritis (RA) patients are at increased risk of cardiovascular disease (CVD). Methotrexate (MTX), a mainstay in the treatment of RA, appears to mitigate…
Abstract Number: 927 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results
Rene Westhovens¹, William F.C. Rigby ², Désirée van der Heijde ³, Daniel W.T. Ching ⁴, Beatrix Bartok ⁵, Franziska Matzkies ⁵, Zhaoyu Yin ⁵, Ying Guo ⁵, Chantal Tasset ⁶, John Sundy ⁵, Neelufar Mozaffarian ⁵, Osvaldo Daniel Messina ⁷, Robert B.M. Landewé ⁸, Tatsuya Atsumi ⁹ and Gerd Burmester ¹⁰, ¹University Hospitals, Leuven, Belgium, ²Dartmouth College, Lebanon, NH, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Timaru Hospital, Timaru, New Zealand, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Cosme Argerich Hospital and IRO Medical Center, Buenos Aires, Argentina, ⁸Amsterdam University Medical Center, Amsterdam, Netherlands, ⁹Hokkaido University, Sapporo, Japan, ¹⁰Charité—University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL), an orally administered, potent, selective inhibitor of Janus kinase 1 (JAK1), has shown good efficacy and was well tolerated for treatment of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].